>>> RTR - OPEC confidential report sees market share squeeze to 2019

  • DEMAND FOR OPEC CRUDE SEEN UNDER DOWNWARD PRESSURE UNTIL 2019 UNLESS NON-OPEC SUPPLY FALLS FASTER THAN EXPECTED – DRAFT OPEC STRATEGY REPORT
EXCLUSIVE-OPEC confidential report sees market share squeeze to 2019

  • Report sees demand for OPEC crude falling in next few years
  • Iran recommends OPEC set price target, adjust output
  • Report assumes $55 oil in 2015, rising $5/year to 2020
  • Report supports view OPEC to gain market share in long run
Nov 4 (Reuters) - Global demand for OPEC's crude oil will remain under pressure in the next few years, the producer group said in an internal report, potentially fuelling a debate on its strategy of defending market share rather than prices.
The draft report of OPEC's long-term strategy, seen by Reuters, forecasts crude supply from OPEC - which has an output target of 30 million barrels per day (bpd) - falling slightly from 2015's level until 2019, unless output slows faster than expected in rival producers.
OPEC governors, official representatives of the 12 members of the Organization of the Petroleum Exporting Countries, met at the group's Vienna headquarters on Wednesday to approve the final draft of the report.
The 44-page report, marked "CONFIDENTIAL," includes an annex containing comments from two members, Iran and Algeria, suggesting OPEC return to its old policy of propping up prices at a desired level by adjusting supplies.
"Reaching agreement on a fair and reasonable price of oil for the next six to 12 months" is one of the steps that Iran recommends OPEC take. "OPEC production ceiling should be set for six or 12 months intervals."
OPEC oil ministers meet on Dec. 4 to decide whether to extend the strategy of allowing prices to fall to slow higher-cost rival supply. Since November 2014, when the group adopted that policy, OPEC production has risen but prices have deepened their collapse, hurting oil revenue.
The report sees only a gentle recovery over the next few years in oil prices LCOc1, which have more than halved to $50 a barrel since June 2014 due to plentiful supply.
OPEC's basket of crude oils is assumed in the report at $55 in 2015 and to rise by $5 a year to reach $80 by 2020.

LONG-TERM GAIN IN MARKET SHARE
Saudi Arabia, supported by other relatively wealthy Gulf members, led the change in strategy last year. Riyadh shows no sign of changing course, seeing the approach as long-term.
The draft report supports the view that OPEC's market share will rise in the long run as output of shale oil, also known as tight oil, and natural gas liquids (NGLs) is curbed.
"It is ... assumed that tight crude and unconventional NGL supply will reach a maximum at some point after 2020 and then start to decline slightly," the report said.
"As a result of non-OPEC supply developments, OPEC crude is expected to rise over the long term, reaching 40.7 million bpd in 2040. Moreover, the share of OPEC crude in the world liquids supply in 2040 is 37 percent, which is above current levels of around 33 percent."
Over the long run, as non-OPEC supply growth fades, the report assumes oil will rise further and its nominal price will reach $162, or $95 in 2014 dollars.
But a chart in the report also presents a scenario in which non-OPEC supply is more resilient, putting increased downward pressure on the group's market share and highlighting the uncertainty over future demand for OPEC oil.
"OPEC crude production would reach its lowest point in this scenario at 28.7 million bpd in 2023," the report said.
"The resulting range for OPEC crude in 2040 amounts to 9.4 million bpd, which highlights the challenges for member countries' long-term investment decisions."
OPEC publishes long-term strategy reports every five years. Its 2010 report did not mention shale oil as a serious competitor, highlighting the dramatic change the oil market has undergone in the past few years.
The long-term report, prepared by OPEC's research team in Vienna, traditionally cautions that it does not articulate the final position of OPEC or any member country on any proposed conclusions it contains.

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
: LINC +27.7%, EFOI +16.1%, ARCO +10.7%, SHOP +8.6%, CHK +5.8%, BSFT +5.8%, VSI +5.2%, CBB +4.3%, KORS +4.3%, LGIH +4%, WEN +3.8%, KEG +3.5%, CLMT +3.5%, ARRY +3.3%, VG +2.9%, REGN +2.1%, HL +1.9%, VIRT +1.8%, SBGI +1.7%, GDP +1.2%, AGN +1.2%, CAPL +1.2%, SNH +1.1%, MRD +0.9%

M&A news: MR +6.5% (to be taken private for $28/share)

Select metals/mining stocks trading higher: BBL +2.7%, BHP +2.3%, RIO +2.3%, FCX +2.3%, VALE +1.7%, GOLD +1.6%, AA +1%

Other news: VVUS +10.9% (still checking, expected to report today), FLTX +4% (acquired SAAS fleet mgmt solutions firm Visirun S.p.A.; terms not disclosed), TASR +3.5% (rebounding modestly following yday's decline), CSIQ +2% (submits Form S-1 to the SEC)relating to the proposed IPO of common equity of a YieldCo vehicle), SUNE +1.8% (Bloomberg details news that SunEdison has secured $500 MW India solar project), NRF +1.5% (declares post spin quarterly dividend of $0.75/share), SLW +1.4% (acquired silver stream from Glencore's Antamina mine; co also reported earnings), MDXG +0.8% (to post a document to rectify misinterpretations arising from the publication of the FDA's proposed Draft Guidance on HCT/Ps)

Analyst comments: OPXA +5.9% ( initiated with a Buy at Chardan Capital Market), BDSI +3% (initiated with a Buy at Cantor Fitzgerald), TMH +2% (upgraded to Buy from Neutral at BofA/Merrill)

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
: SCMP -16.6%, RSO -9%, AVP -8.1%, MEMP -7.3%, CKP -6.5%, CLH -5%, SSYS -4.5%, DDD -4.2%, NAVB -3.6%, VOYA -3.6%, WCG -3%, LL -3%, ORA -2.5%, ENLK -2.1%, MNTA -1.8%, FOX -1.6%, PHG -1.4%, NRG -0.9%, WD -0.9%

Other news: EMES -14.4% (following 50% move higher yesterday), NBG -12.3% (still checking), HCHC -7.9% ( announces a proposed offering of $50 mln in common stock), BIOD -4.5% (entered into a restructuring plan), UNTD -4.4% (President and CEO Francis Lobo to resign effective November 18), BAH -4.1% ( announces secondary offering of 13M shares of Class A common stock by an affiliate of The Carlyle Group ), AKS -2.4% (in symp with X), XOMA -1.6% (regained compliance with Nasdaq's minimum bid price requirement; Jim Neal named Chief Operating Officer), XOMA -1.6% (regains compliance with Nasdaq's minimum bid price requirement, names Jim Neal as Chief Operating Officer)

Analyst comments: MNKD -5.3% (downgraded to Underperform at RBC Capital Mkts; tgt lowered to $1), GNW -2.7% (downgraded to Sell from Neutral at UBS), PRAH -2.5% (downgraded to Underperform at Avondale), PAAS -1% (downgraded to Underperform at BMO Capital), SSRI -0.7% (downgraded to Market Perform at BMO Capital
)

>>> U.S. Senators Susan Collins (R-ME) and Claire McCaskill (D-MO) plan to intro

U.S. Senators Susan Collins (R-ME) and Claire McCaskill (D-MO) plan to introduce Senate investigation over drug pricing

  • Senate Investigation Release. Stocks mentioned in Senator's investigation include: Valeant Pharmaceuticals (VRX) & Retrophin (RTRX).
  • This follows news that House Democrats will hold a conference call today at 9:30am ET (Democrats Oversight Information for Event).
  • Some other names to monitor: Endo Pharm (ENDP), Horizon Pharma (HZNP), Allergan (AGN) among others.